Laboratory of Toxicology and Pharmacology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Mol Cell Biol. 2011 Feb;31(3):466-81. doi: 10.1128/MCB.00847-10. Epub 2010 Dec 6.
Hepatocyte nuclear factor 4α (HNF4α) controls the expression of many critical metabolic pathways, and the Mediator complex occupies a central role in recruiting RNA polymerase II (Pol II) to these gene promoters. An impaired transcriptional HNF4α network in human liver is responsible for many pathological conditions, such as altered drug metabolism, fatty liver, and diabetes. Here, we report that Med25, an associated member of the Mediator complex, is required for the association of HNF4α with Mediator, its several cofactors, and RNA Pol II. Further, increases and decreases in endogenous Med25 levels are reflected in the composition of the transcriptional complex, Pol II recruitment, and the expression of HNF4α-bound target genes. A novel feature of Med25 is that it imparts "selectivity." Med25 affects only a significant subset of HNF4α target genes that selectively regulate drug and lipid metabolism. These results define a role for Med25 and the Mediator complex in the regulation of xenobiotic metabolism and lipid homeostasis.
肝细胞核因子 4α(HNF4α)控制着许多关键代谢途径的表达,而中介体复合物在将 RNA 聚合酶 II(Pol II)招募到这些基因启动子中起着核心作用。人类肝脏中受损的转录 HNF4α 网络是许多病理状况的原因,如药物代谢改变、脂肪肝和糖尿病。在这里,我们报告说,中介体复合物的相关成员 Med25 对于 HNF4α 与中介体、其几个共因子和 RNA Pol II 的结合是必需的。此外,内源性 Med25 水平的增加和减少反映在转录复合物的组成、Pol II 的募集和 HNF4α 结合靶基因的表达上。Med25 的一个新特点是它赋予了“选择性”。Med25 仅影响一小部分 HNF4α 靶基因,这些基因选择性地调节药物和脂质代谢。这些结果定义了 Med25 和中介体复合物在调节异生物质代谢和脂质稳态中的作用。